A Randomized Controlled Trial of Misoprostol and Sulprostone to End Pregnancy after Fetal Death

Objective. To compare effectiveness, side effects, and patients' perception of vaginal misoprostol versus intravenous sulprostone for ending pregnancy after fetal death between 14 and 42 weeks gestation. Method. Multicenter randomized controlled trial, using block randomization, central alloca...

Full description

Saved in:
Bibliographic Details
Main Authors: Kristin Van Mensel, Filip Claerhout, Patrick Debois, Marc J. N. C. Keirse, Myriam Hanssens
Format: Article
Language:English
Published: Wiley 2009-01-01
Series:Obstetrics and Gynecology International
Online Access:http://dx.doi.org/10.1155/2009/496320
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832551562325524480
author Kristin Van Mensel
Filip Claerhout
Patrick Debois
Marc J. N. C. Keirse
Myriam Hanssens
author_facet Kristin Van Mensel
Filip Claerhout
Patrick Debois
Marc J. N. C. Keirse
Myriam Hanssens
author_sort Kristin Van Mensel
collection DOAJ
description Objective. To compare effectiveness, side effects, and patients' perception of vaginal misoprostol versus intravenous sulprostone for ending pregnancy after fetal death between 14 and 42 weeks gestation. Method. Multicenter randomized controlled trial, using block randomization, central allocation, and prior power analysis. Outcome measures. Induction-delivery interval, gastrointestinal side effects, use of analgesia, pain perception, pyrexia, placental retention, hemorrhage, and women's opinions. Results. Of 176 women aimed for, 143 were randomized over 7 years, of whom 4 were excluded. There was no difference in delivery within 24 and 36 hours: 91.4% and 97.1% with misoprostol (𝑛=70) versus 85.5% and 92.8% with sulprostone (𝑛=69). There was no difference in either gastrointestinal side effects, as reported by the women and their caregivers, use of analgesia, women's pain perception, blood loss or placental retention. Hyperthermia ≥38°C was more common with misoprostol (24.3%) than with sulprostone (11.6%; difference: +12.7%; 95% CI: +1.2% to +25.3%) and related to the total dose used. Acceptability of both induction methods was similar except for freedom of movement, which was substantially in favor of misoprostol (lack of freedom reported with misoprostol in 34.3% versus 63.8% with sulprostone; difference: −29.5%; 95% CI: −13.6% to −45.4%). Conclusions. Misoprostol and sulprostone are similarly effective with little difference in side effects except for hyperthermia, related to the dose of misoprostol used, and women's reported lack of mobility with intravenous sulprostone. Effectiveness of both methods increased with gestational age.
format Article
id doaj-art-bcbb51725e2e4af8b25fc08022a74144
institution Kabale University
issn 1687-9589
1687-9597
language English
publishDate 2009-01-01
publisher Wiley
record_format Article
series Obstetrics and Gynecology International
spelling doaj-art-bcbb51725e2e4af8b25fc08022a741442025-02-03T06:01:15ZengWileyObstetrics and Gynecology International1687-95891687-95972009-01-01200910.1155/2009/496320496320A Randomized Controlled Trial of Misoprostol and Sulprostone to End Pregnancy after Fetal DeathKristin Van Mensel0Filip Claerhout1Patrick Debois2Marc J. N. C. Keirse3Myriam Hanssens4Women and Children Division, Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, 3000 Leuven, BelgiumWomen and Children Division, Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, 3000 Leuven, BelgiumWomen and Children Division, Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, 3000 Leuven, BelgiumWomen and Children Division, Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, 3000 Leuven, BelgiumWomen and Children Division, Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, 3000 Leuven, BelgiumObjective. To compare effectiveness, side effects, and patients' perception of vaginal misoprostol versus intravenous sulprostone for ending pregnancy after fetal death between 14 and 42 weeks gestation. Method. Multicenter randomized controlled trial, using block randomization, central allocation, and prior power analysis. Outcome measures. Induction-delivery interval, gastrointestinal side effects, use of analgesia, pain perception, pyrexia, placental retention, hemorrhage, and women's opinions. Results. Of 176 women aimed for, 143 were randomized over 7 years, of whom 4 were excluded. There was no difference in delivery within 24 and 36 hours: 91.4% and 97.1% with misoprostol (𝑛=70) versus 85.5% and 92.8% with sulprostone (𝑛=69). There was no difference in either gastrointestinal side effects, as reported by the women and their caregivers, use of analgesia, women's pain perception, blood loss or placental retention. Hyperthermia ≥38°C was more common with misoprostol (24.3%) than with sulprostone (11.6%; difference: +12.7%; 95% CI: +1.2% to +25.3%) and related to the total dose used. Acceptability of both induction methods was similar except for freedom of movement, which was substantially in favor of misoprostol (lack of freedom reported with misoprostol in 34.3% versus 63.8% with sulprostone; difference: −29.5%; 95% CI: −13.6% to −45.4%). Conclusions. Misoprostol and sulprostone are similarly effective with little difference in side effects except for hyperthermia, related to the dose of misoprostol used, and women's reported lack of mobility with intravenous sulprostone. Effectiveness of both methods increased with gestational age.http://dx.doi.org/10.1155/2009/496320
spellingShingle Kristin Van Mensel
Filip Claerhout
Patrick Debois
Marc J. N. C. Keirse
Myriam Hanssens
A Randomized Controlled Trial of Misoprostol and Sulprostone to End Pregnancy after Fetal Death
Obstetrics and Gynecology International
title A Randomized Controlled Trial of Misoprostol and Sulprostone to End Pregnancy after Fetal Death
title_full A Randomized Controlled Trial of Misoprostol and Sulprostone to End Pregnancy after Fetal Death
title_fullStr A Randomized Controlled Trial of Misoprostol and Sulprostone to End Pregnancy after Fetal Death
title_full_unstemmed A Randomized Controlled Trial of Misoprostol and Sulprostone to End Pregnancy after Fetal Death
title_short A Randomized Controlled Trial of Misoprostol and Sulprostone to End Pregnancy after Fetal Death
title_sort randomized controlled trial of misoprostol and sulprostone to end pregnancy after fetal death
url http://dx.doi.org/10.1155/2009/496320
work_keys_str_mv AT kristinvanmensel arandomizedcontrolledtrialofmisoprostolandsulprostonetoendpregnancyafterfetaldeath
AT filipclaerhout arandomizedcontrolledtrialofmisoprostolandsulprostonetoendpregnancyafterfetaldeath
AT patrickdebois arandomizedcontrolledtrialofmisoprostolandsulprostonetoendpregnancyafterfetaldeath
AT marcjnckeirse arandomizedcontrolledtrialofmisoprostolandsulprostonetoendpregnancyafterfetaldeath
AT myriamhanssens arandomizedcontrolledtrialofmisoprostolandsulprostonetoendpregnancyafterfetaldeath
AT kristinvanmensel randomizedcontrolledtrialofmisoprostolandsulprostonetoendpregnancyafterfetaldeath
AT filipclaerhout randomizedcontrolledtrialofmisoprostolandsulprostonetoendpregnancyafterfetaldeath
AT patrickdebois randomizedcontrolledtrialofmisoprostolandsulprostonetoendpregnancyafterfetaldeath
AT marcjnckeirse randomizedcontrolledtrialofmisoprostolandsulprostonetoendpregnancyafterfetaldeath
AT myriamhanssens randomizedcontrolledtrialofmisoprostolandsulprostonetoendpregnancyafterfetaldeath